Main Article Content
The article provides the data on the immunological mechanisms of type 1 diabetes mellitus (T1DM) on the preclinical and early clinical stages of disease formation on the basis of studying the features of T1DM pathogenesis, monitoring the process of autoimmune destruction of insulin-producing β-cells by determining the content of diabetes-associated auto-antibodies (the incidence and titers dynamics), the study of the characteristics of cytokine secretion on the pre-clinical stage of T1DM development in children and adolescents. Introduction of new approaches to pre-clinical diagnosis of T1DM allowed determine the group of marker-positive children with burdened heredity and predictable risk of disease development. The study involved 450 healthy normoglycemic children and adolescents aged from 7 to 15 years old. It was revealed that 94 (26.7 %) of 366 children with burdened hereditary by at least two-fold determination of DAAb had an increased DAAb titer, mainly GADA and IA-2A, the clinical debut of T1DM manifested in 49 (52.1 %) of them from 6 months to 12 years (30.9 ± 3.2 months). T1DM developed in the same period in a child, that was 0.8 % of the 272 (73.3 %) DAAb-negative children. There was determined a formula of combined incidence and values of simultaneously elevated DAAb titers to islet autoantigens, namely IA-2A + GADA, which are predictor of the duration of T1DM pre-clinical stage and debut occurrence. It has been also established a disturbance of cytokine production (increased level of pro-inflammatory cytokines IL-1α, IL-6 and FNO-α, IL-8 and IL-16 while reduced concentration of IL-4 in blood plasma) as a key factor in the T1DM pathogenesis that causes the debut occurrence, and aggressiveness of its course.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
Зак К.П., Попова В.В. Цитокины и сахарный диабет 1-го типа у человека (обзор с включением собственных данных) // Укр. мед. часопис. — 2006. — № 1 (51). — C. 78-89.
A longitudinal study of GAD65 and ICA512 autoantibo-dies during the progression to type 1 diabetes in Diabetes Prevention Trial — Type 1 (DPT-1) participants / Sosenko J.M., Skyler J.S., Pal-mer J.P. // Diabetes Care. — 2011. — Vol. 34, № 11. — P. 2435-2437.
Atkinson M.A. The pathogenesis and natural history of type 1 diabetes // Cold Spring Harb. Perspect. Med. — 2012; 2:a007641
Atkinson M.A. Thirty years of investigating the autoimmune basis for type 1 diabetes: Why can’t we prevent or reverse this di-sease // Diabetes. — 2005. — Vol. 54, № 5. — P. 1253-1263.
Atkinson M.A. Type 1 diabetes / M.A. Atkinson, G.S. Eisenbarth, A.W. Michels // Lancet. — 2014. — Vol. 383, № 9911. — P. 69-82.
Autoantibodies in diabetes / C. Pihoker, L.K. Gilliam, Ch.S. Hampe, Å. Lernmark // Diabetes. — 2005. — Vol. 54, Suppl. 2. — P. S52-S61.
Baggiolini M. Chemokines in pathology and medicine // J. Intern. Med. — 2001. — Vol. 250. — P. 9100-9104.
Battaglia M., Atkinson M.A. The streetlight effect in Type 1 diabetes // Diabetes. — 2015. — Vol. 64. — P. 1081-1090.
Bingley P.J. Interactions of age, islet cell antibodies, insulin autoantibodies, and first-phase insulin response in predicting risk of progression to IDDM in ICA + relatives. The ICARUS Data Set // Diabetes. — 1996. — Vol. 45. — P. 1720-1728.
Cytokines and β-cell biology: from concept to clinical translation / M.Y. Donath, J. Storling, L.A. Berchtold et al. // Endocr. Rev. — 2008. — Vol. 29. — P. 334-350.
Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk / V. Parikka, K. Näntö-Salonen, M. Saari-nen et al. // Diabetologia. — 2012. — Vol. 55, № 7. — P. 1926-1936.
Effect of anti-inflammatory cytokines on insulin-producing cells / E. Gurgel-Convey, K.L. A. Soura, M. Elsner, S. Lensen // Diabetologia. — 2007. — Vol. 47, Suppl. 1. — P. 460.
Elevated serum levels of macrophage-derived cytokines precede and accompany the onset of IDDM / M.J. Hussain, M. Peakman, H. Gallati et al. // Diabetologia. — 1996. — Vol. 39, № 1. — P. 60-69.
Evidence that HLA class I and II associations with type 1 diabetes, autoantibodies to GAD and autoantibodies to IA-2, are distinct / J.M.M. Howson, H. Stevens, D.J. Smyth et al. // Diabetes. — 2011. — Vol. 60, № 10. — P. 2635-2644.
GAD autoantibody affinity in schoolchildren from the ge-neral population / Ch. Bender, M. Schlosser, U. Christen et al. // Diabetologia. — 2014. — Vol. 57. — P. 1911-1918.
High levels of circulating interleukin-10 in diabetic nephropathy patients / J. Mysliwska, K. Zorena, E. Semetkowska-Jurkiewicz et al. // Eur. Cytokine Netw. — 2005. — Vol. 16, № 2. — P. 117-122.
IFN-γ low production capacity in type 1 diabetes mellitus patients at onset of disease / M.A. Avanzini, L. Ciardelli, E. Lenta et al. // Exp. Clin. Endocrinol. Diabetes. — 2005. — Vol. 113, № 6. — P. 1-5.
Inflammatory cytokine, growth factor and counter-regulatory responses to exercise in children with type 1 diabetes and healthy controls / P.R. Galassetti, K. Iwanaga, M. Crisostomo et al. // Pediatr. Diabetes. — 2006. — Vol. 7, № 1. — P. 16-24.
Kolb H. An immune origin of type 2 diabetes? / H. Kolb, T. Mandrup-Poulsen // Diabetologia. — 2005. — Vol. 48, № 6. — P. 1038-1050.
Lebastchi J. Immunologic and metabolic biomarkers of β-cell destruction in the diagnosis of type 1 diabetes / J. Lebastchi, K.C. He-rold // Cold Spring Harb. Perspect. Med. — 2012; 2:a007708.
Lo Hui-Chen. The relationship among serum cytokines, chemokine, nitric oxide, and leptin in children with type 1 diabetes mellitus / Hui-Chen Lo, Su-Chen Lin, Yu-Mei Wang // Clin. Biochem. — 2004. — Vol. 37, № 8. — P. 666-672.
Mediators of inflammation in children with type 1 diabetes mellitus: cytokines in type 1 diabetic children / A.B. Erbagci, M. Tarakcioglu, Y. Coskun et al. // Clin. Biochem. — 2001. — Vol. 34, № 8. — P. 645-650.
Multiple immuno-regulatory defects in type 1 diabetes / A. Kukreja, G. Cost, J. Marker et al. // J. Clin. Invest. — 2002. — Vol. 109, № 1. — P. 131-140.
Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial — Type 1 / R.T. Orban, J.M. Sosenko, D. Cuthbertson et al. // Diabetes Care. — 2009. — Vol. 32. — P. 2269-2274.
Pietropaolo M. Humoral autoimmunity in type 1 diabetes: prediction, significance, and detection of distinct disease subtypes / M. Pietropaolo, R. Towns, G.S. Eisenbarth // Cold Spring Harb. Perspect. Med. — 2012; 2:a012831.
Predictive characteristics of diabetes-associated autoantibodies among children with HLA-conferred disease susceptibility in the general population / H.T.A. Siljander, S. Simell, A. Hekkala et al. // Diabetes. — 2009. — Vol. 58. — P. 2835-2842.
Primer: immunity and autoimmunity / M. Pietropaolo, J.M. Surhigh, P.W. Nelson, G.S. Eisenbarth // Diabetes. — 2008. — Vol. 57. — P. 2872-2882.
Progression from single to multiple islet autoantibodies often occurs soon after seroconversion: implications for early screening / R. Chmiel, E.Z. Giannopoulou, Ch. Winkler et al. // Diabetologia. — 2015. — Vol. 58, № 2. — P. 411-413.
Regulatory vs. inflammatory cytokine T-cell responses to mutated insulin peptides in healthy and type 1 diabetic subjects / M. Nakayamaa, K. McDaniela, L. Fitzgerald-Millera et al. // PNAS. — 2015. — Vol. 112, № 14. — P. 4429-4434.
Role of immune dysfunction in pathogenesis of type 1 diabetes mellitus in children / Jin-Shui He, Pu-Song Xie, Dao-Shu Luo et al. // Asian Pacific J. Tropical Medicine. — 2014. — P. 823-826.
Schneider D.A. Potential viral pathogenic mechanism in human type 1 diabetes / D.A. Schneider, M.G. von Herrath // Diabetologia. — 2014. — Vol. 57. — P. 2009-2018.
Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children / A.G. Ziegler, M. Rewers, O. Simell et al. // JAMA. — 2013. — Vol. 309, № 23. — P. 2473-2479.
Serum titres of anti-glutamic acid decarboxylase-65 and anti-IA-2 autoantibodies are associated with different immuno-regulatory milieu in newly diagnosed type 1 diabetes patients / M.A.L. Gabbay, M.N. Sato, A.J.S. Duarte, S.A. Dib // Clin. Exp. Immunol. — 2012. — Vol. 168, № 1. — P. 60-67.
Serum IL-1β, IL-2, and IL-6 in insulin-dependent diabetic children / Y. Dogan, S. Akarsu, B. Ustundag et al. // Hindawi Publishing Corporation Mediators of Inflammation. — 2006. — Vol., Article ID 59206. — P. 1-6.
Sherry N.A. Natural history of β-cell function in type 1 diabetes / N.A. Sherry, E.B. Tsai, K.C. Herold // Diabetes. — 2005. — Vol. 54, Suppl. 2. — P. S32-S39.
Standards of medical care in diabetes — 2015 // Diabetes care. — 2015. — Vol. 38, Suppl. 1. — S1-S90.
The prediction of type 1 diabetes by multiple autoantibody le-vels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients / J.M. Sosenko, J.S. Skyler, J.P. Palmer et al. // Diabetes Care. — 2013. — Vol. 36, № 9. — P. 2615-2620.
Type 1 diabetes is associated with increased cyclooxygenase — and cytokine–mediated inflammation / S. Basu, A. Larsson, J. Vessby et al. // Diabetes Care. — 2005. — Vol. 28, № 6. — P. 1371-1375.